Regeneron第三季度的盈利超出预期，尽管内部销售仍推动其股价上涨。 Regeneron beat earnings expectations in Q3, driving its stock up despite insider sales.

Regenenron制药公司报告Q3收入丰厚,EPS收入为11.83美元,收入为37.5亿美元,超过了预期。 Regeneron Pharmaceuticals reported strong Q3 earnings, with EPS of $11.83 and revenue of $3.75 billion, exceeding expectations. 股票涨至769.69美元,在斯科舍银行的援助下,将价格目标提高到770美元。 The stock rose to $769.69, aided by Scotiabank raising its price target to $770. 分析员预测全年EPS为35.92美元,该股票享有“机动购买”共识评级。 Analysts project full-year EPS of $35.92, and the stock holds a "Moderate Buy" consensus rating. 机构所有权仍然高达83.31%,内部人士,包括主任Christine A. Poon和VP Jason Pitofsky出售股票。 Institutional ownership remains high at 83.31%, while insiders including Director Christine A. Poon and VP Jason Pitofsky sold shares. 该公司宣布的季度红利为0.88美元,收益率为0.5%。 The company declared a quarterly dividend of $0.88, with a 0.5% yield. EYLEA仍然是其输油管中的一个关键产品。 EYLEA remains a key product in its pipeline.